From April 1, 2023 to June 30, 2023, the company has repurchased 173,900 shares, representing 1.44% for CAD 1.28 million. With this, the company has completed the repurchase of 226,700 shares, representing 1.87% for CAD 1.67 million under the buyback announced on December 13, 2022.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
8.24 CAD | -1.55% | -3.17% | -10.63% |
04-22 | BioSyent Inc.(TSXV:RX) dropped from S&P/TSX Venture Composite Index | CI |
04-01 | BioSyent To Present At LD Micro New York Investor Conference | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-10.63% | 71.16M | |
+31.37% | 588B | |
-2.79% | 364B | |
+20.55% | 326B | |
+5.49% | 285B | |
+14.83% | 239B | |
+9.93% | 210B | |
-6.95% | 200B | |
+10.96% | 167B | |
+0.23% | 161B |
- Stock Market
- Equities
- RX Stock
- News BioSyent Inc.
- Tranche Update on BioSyent Inc. (TSXV: RX)'s Equity Buyback Plan announced on December 13, 2022.